Literature DB >> 34037664

Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?

Derek S Chew1, Daniel B Mark1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34037664     DOI: 10.1001/jamacardio.2021.1448

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  2 in total

1.  Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial.

Authors:  Derek S Chew; Patricia A Cowper; Hussein Al-Khalidi; Kevin J Anstrom; Melanie R Daniels; Linda Davidson-Ray; Yanhong Li; Robert E Michler; Julio A Panza; Ileana L Piña; Jean L Rouleau; Eric J Velazquez; Daniel B Mark
Journal:  Circulation       Date:  2022-01-19       Impact factor: 29.690

2.  Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure.

Authors:  Birju R Rao; Candace D Speight; Larry A Allen; Scott D Halpern; Yi-An Ko; Daniel D Matlock; Miranda A Moore; Alanna A Morris; Laura D Scherer; Mary C Thomson; Peter Ubel; Neal W Dickert
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.